Mechanism of immunomodulatory drugs in multiple myeloma

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F12%3A00057538" target="_blank" >RIV/00216224:14110/12:00057538 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.leukres.2012.05.010" target="_blank" >http://dx.doi.org/10.1016/j.leukres.2012.05.010</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.leukres.2012.05.010" target="_blank" >10.1016/j.leukres.2012.05.010</a>

Result language
angličtina
Original language name
Mechanism of immunomodulatory drugs in multiple myeloma
Original language description
Multiple myeloma is the second most common hematological cancer in the world. It is characterized by accumulation of malignant plasma cells in the bone marrow, osteolytic lesions and monoclonal immunoglobulins in blood/urine. With the introduction of immunomodulatory drugs into the treatment protocol, the outcome of multiple myeloma patients has dramatically improved with more than 30% of patients surviving for 10 years thus shifting multiple myeloma to a treatable condition.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)